191 research outputs found
Target DNA Structure Plays a Critical Role in RAG Transposition
Antigen receptor gene rearrangements are initiated by the RAG1/2 protein complex, which recognizes specific DNA sequences termed RSS (recombination signal sequences). The RAG recombinase can also catalyze transposition: integration of a DNA segment bounded by RSS into an unrelated DNA target. For reasons that remain poorly understood, such events occur readily in vitro, but are rarely detected in vivo. Previous work showed that non-B DNA structures, particularly hairpins, stimulate transposition. Here we show that the sequence of the four nucleotides at a hairpin tip modulates transposition efficiency over a surprisingly wide (>100-fold) range. Some hairpin targets stimulate extraordinarily efficient transposition (up to 15%); one serves as a potent and specific transposition inhibitor, blocking capture of targets and destabilizing preformed target capture complexes. These findings suggest novel regulatory possibilities and may provide insight into the activities of other transposases
A Prospective Open Trial of Guanfacine in Children with Pervasive Developmental Disorders
Objective:
A common complaint for children with pervasive developmental disorder (PDD) is hyperactivity.
The purpose of this pilot study was to gather preliminary information on the efficacy of guanfacine in
children with PDD and hyperactivity.
Methods:
Children with PDD accompanied by hyperactivity entered the open-label trial if there was a recent
history of failed treatment with methylphenidate or the child did not improve on methylphenidate in a
multisite, placebo-controlled trial.
Results:
Children (23 boys and 2 girls) with a mean age of 9.03 (±3.14) years entered the open-label trial.
After 8 weeks of treatment, the parent-rated Hyperactivity subscale of the Aberrant Behavior Checklist
(ABC) went from a mean of 31.3 (±8.89) at baseline to 18.9 (±10.37) (effect size = 1.4; p < 0.001). The
teacher-rated Hyperactivity subscale decreased from a mean of 29.9 (±9.12) at baseline to 22.3 (±9.44)
(effect size = 0.83; p < 0.01). Twelve children (48%) were rated as Much Improved or Very Much
Improved on the Clinical Global Impressions– Improvement. Doses ranged from 1.0 to 3.0 mg/day in two
or three divided doses. Common adverse effects included irritability, sedation, sleep disturbance (insomnia
or midsleep awakening), and constipation. Irritability led to discontinuation in 3 subjects. There were no
significant changes in pulse, blood pressure, or electrocardiogram.
Conclusions:
Guanfacine may be useful for the treatment of hyperactivity in children with PDD. Placebocontrolled
studies are needed to guide clinical practice
Moderators, Mediators, and Other Predictors of Risperidone Response in Children with Autistic Disorder and Irritability
Objective/Background:
The National Institute of Mental Health (NIMH) Research Units on Pediatric Psychopharmacology
(RUPP) Autism Network found an effect size of d = 1.2 in favor of risperidone on the main outcome measure
in an 8-week double-blind, placebo-controlled trial for irritabilityin autistic disorder. This paper explores
moderators and mediators of this effect.
Method:
Intention-to-treat (ITT) analyses were conducted with suspected moderators and mediators entered
into the regression equations. MacArthur Foundation Network subgroup guidelines were followed in the
evaluation of the results.
Results:
Only baseline severity moderated treatment response: Higher severity showed greater improvement
for risperidone but not for placebo. Weight gain mediated treatment response negatively: Those who gained
more weight improved less with risperidone and more with placebo. Compliance correlated with outcome for
risperidone but not placebo. Higher dose correlated with worse outcome for placebo, but not risperidone. Of
nonspecific predictors, parent education, family income, and low baseline prolactin positively predicted
outcome; anxiety, bipolar symptoms, oppositional-defiant symptoms, stereotypy, and hyperactivity
negatively predicted outcome. Risperidone moderated the effect of change in 5'-nucleotidase, a marker of
zinc status, for which decrease was associated with improvement only with risperidone, not with placebo.
Conclusion:
The benefit–risk ratio of risperidone is better with greater symptom severity. Risperidone can be
individually titrated to optimal dosage for excellent response in the majority of children. Weight gain is not
necessary for risperidone benefit and may even detract from it. Socioeconomic advantage, low prolactin, and
absence of co-morbid problems non-specifically predict better outcome. Mineral interactions with
risperidone deserve further study
Cognitive Effects of Risperidone in Children with Autism and Irritable Behavior
Objective:
The objective of this research was to explore the effects of risperidone on cognitive processes in
children with autism and irritable behavior.
Method:
Thirty-eight children, ages 5-17 years with autism and severe behavioral disturbance, were
randomly assigned to risperidone (0.5 to 3.5 mg/day) or placebo for 8 weeks. This sample of 38 was a subset
of 101 subjects who participated in the clinical trial; 63 were unable to perform the cognitive tasks. A
double-blind placebo-controlled parallel groups design was used. Dependent measures included tests of
sustained attention, verbal learning, hand-eye coordination, and spatial memory assessed before, during, and
after the 8-week treatment. Changes in performance were compared by repeated measures ANOVA.
Results:
Twenty-nine boys and 9 girls with autism and severe behavioral disturbance and a mental age ≥18
months completed the cognitive part of the study. No decline in performance occurred with risperidone.
Performance on a cancellation task (number of correct detections) and a verbal learning task (word
recognition) was better on risperidone than on placebo (without correction for multiplicity). Equivocal
improvement also occurred on a spatial memory task. There were no significant differences between
treatment conditions on the Purdue Pegboard (hand-eye coordination) task or the Analog Classroom Task
(timed math test).
Conclusion:
Risperidone given to children with autism at doses up to 3.5 mg for up to 8 weeks appears to have no
detrimental effect on cognitive performance
Recommended from our members
Individual common variants exert weak effects on the risk for autism spectrum disorders.
While it is apparent that rare variation can play an important role in the genetic architecture of autism spectrum disorders (ASDs), the contribution of common variation to the risk of developing ASD is less clear. To produce a more comprehensive picture, we report Stage 2 of the Autism Genome Project genome-wide association study, adding 1301 ASD families and bringing the total to 2705 families analysed (Stages 1 and 2). In addition to evaluating the association of individual single nucleotide polymorphisms (SNPs), we also sought evidence that common variants, en masse, might affect the risk. Despite genotyping over a million SNPs covering the genome, no single SNP shows significant association with ASD or selected phenotypes at a genome-wide level. The SNP that achieves the smallest P-value from secondary analyses is rs1718101. It falls in CNTNAP2, a gene previously implicated in susceptibility for ASD. This SNP also shows modest association with age of word/phrase acquisition in ASD subjects, of interest because features of language development are also associated with other variation in CNTNAP2. In contrast, allele scores derived from the transmission of common alleles to Stage 1 cases significantly predict case status in the independent Stage 2 sample. Despite being significant, the variance explained by these allele scores was small (Vm< 1%). Based on results from individual SNPs and their en masse effect on risk, as inferred from the allele score results, it is reasonable to conclude that common variants affect the risk for ASD but their individual effects are modest
Risperidone Treatment of Autistic Disorder: Longer-Term Benefits and Blinded Discontinuation After 6 Months
Objective: Risperidone is effective for short-term treatment of aggression, temper outbursts, and self-injurious behavior in children with autism. Because these behaviors may be chronic, there is a need to establish the efficacy and safety of longer-term treatment with this agent.
Method: The authors conducted a multisite, two-part study of risperidone in children ages 5 to 17 years with autism accompanied by severe tantrums, aggression, and/or self-injurious behavior who showed a positive response in an earlier 8-week trial. Part I consisted of 4-month open-label treatment with risperidone, starting at the established optimal dose; part II was an 8-week randomized, double-blind, placebo-substitution study of risperidone withdrawal. Primary outcome measures were the Aberrant Behavior Checklist irritability subscale and the Clinical Global Impression improvement scale.
Results: Part I included 63 children. The mean risperidone dose was 1.96 mg/day at entry and remained stable over 16 weeks of open treatment. The change on the Aberrant Behavior Checklist irritability subscale was small and clinically insignificant. Reasons for discontinuation of part I included loss of efficacy (N=5) and adverse effects (N=1). The subjects gained an average of 5.1 kg. Part II included 32 patients. The relapse rates were 62.5% for gradual placebo substitution and 12.5% for continued
risperidone; this difference was statistically significant.
Conclusions: Risperidone showed persistent efficacy and good tolerability for intermediate-length treatment of children with autism characterized by tantrums, aggression, and/or self-injurious behavior. Discontinuation after 6 months was associated with a rapid return of disruptive and aggressive behavior in most subjects
- …